TY  - GEN
AU  - Belshe,R B
AU  - Clements,M L
AU  - Dolin,R
AU  - Graham,B S
AU  - McElrath,J
AU  - Gorse,G J
AU  - Schwartz,D
AU  - Keefer,M C
AU  - Wright,P
AU  - Corey,L
TI  - Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network
SN  - 0022-1899
PY  - 1993///1228
KW  - AIDS Vaccines
KW  - administration & dosage
KW  - Adjuvants, Immunologic
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Animals
KW  - Antibodies, Antinuclear
KW  - immunology
KW  - Cells, Cultured
KW  - Double-Blind Method
KW  - Female
KW  - Gene Products, env
KW  - adverse effects
KW  - Glycosylation
KW  - HIV Envelope Protein gp160
KW  - HIV-1
KW  - Humans
KW  - Lymphocytes
KW  - Male
KW  - Middle Aged
KW  - Protein Precursors
KW  - Safety
KW  - Vaccines, Synthetic
KW  - Vero Cells
N1  - Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S
UR  - https://doi.org/10.1093/infdis/168.6.1387
ER  -